aTyr Pharma (LIFE) Doses Last Patient for ATYR1923 in Pulmonary Sarcoidosis Phase II Trial - Laidlaw
Tweet Send to a Friend
Laidlaw analyst Yale Jen reiterated a Buy rating and $18.00 price target on aTyr Pharma (NASDAQ: LIFE) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
